IDEXX Laboratories (IDXX) Expected to Announce Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) is expected to release its earnings data before the market opens on Monday, February 3rd. Analysts expect IDEXX Laboratories to post earnings of $2.39 per share and revenue of $933.46 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.53 EPS. On average, analysts expect IDEXX Laboratories to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $422.05 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $424.02 and its two-hundred day moving average is $454.59. The company has a market cap of $34.56 billion, a P/E ratio of 40.70, a P/E/G ratio of 3.60 and a beta of 1.36. IDEXX Laboratories has a 12 month low of $398.50 and a 12 month high of $583.39.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IDXX. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Barclays lowered their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $517.29.

Insiders Place Their Bets

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.